» Articles » PMID: 19383972

The Molecular Basis of Hepcidin-resistant Hereditary Hemochromatosis

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2009 Apr 23
PMID 19383972
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction between the hormone hepcidin and the iron exporter ferroportin (Fpn) regulates plasma iron concentrations. Hepcidin binds to Fpn and induces its internalization and degradation, resulting in decreased iron efflux from cells into plasma. Fpn mutations in N144, Y64N, and C326 residue cause autosomal dominant disease with parenchymal iron overload, apparently due to the resistance of mutant Fpn to hepcidin-mediated internalization. To define the mechanism of resistance, we generated human Fpn constructs bearing the pathogenic mutations. The mutants localized to the cell surface and exported iron normally, but were partially or completely resistant to hepcidin-mediated internalization and continued to export iron despite the presence of hepcidin. The primary defect with exofacial C326 substitutions was the loss of hepcidin binding, which resulted in the most severe phenotype. The thiol form of C326 was essential for interaction with hepcidin, suggesting that C326-SH homology is located in or near the binding site of hepcidin. In contrast, N144 and Y64 residues were not required for hepcidin binding, but their mutations impaired the subsequent internalization of the ligand-receptor complex. Our observations explain why the mutations in C326 Fpn residue produce a severe form of hemochromatosis with iron overload at an early age.

Citing Articles

CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis.

Delgado M, Naranjo-Suarez S, Ramirez-Pedraza M, Cardenas B, Gallardo-Martinez C, Balvey A JHEP Rep. 2025; 7(3):101296.

PMID: 39980747 PMC: 11840500. DOI: 10.1016/j.jhepr.2024.101296.


Myeloid Hif2α is not essential to maintain systemic iron homeostasis.

Jain C, Parimi S, Huang W, Hannifin S, Singhal R, Das N Exp Hematol. 2023; 125-126:25-36.e1.

PMID: 37562670 PMC: 11046397. DOI: 10.1016/j.exphem.2023.08.001.


Structural basis of ferroportin inhibition by minihepcidin PR73.

Wilbon A, Shen J, Ruchala P, Zhou M, Pan Y PLoS Biol. 2023; 21(1):e3001936.

PMID: 36649314 PMC: 9882908. DOI: 10.1371/journal.pbio.3001936.


Appropriate Clinical Genetic Testing of Hemochromatosis Type 2-4, Including Ferroportin Disease.

Kowdley D, Kowdley K Appl Clin Genet. 2021; 14:353-361.

PMID: 34413666 PMC: 8369226. DOI: 10.2147/TACG.S269622.


Footprinting Mass Spectrometry of Membrane Proteins: Ferroportin Reconstituted in Saposin A Picodiscs.

Zhou F, Yang Y, Chemuru S, Cui W, Liu S, Gross M Anal Chem. 2021; 93(33):11370-11378.

PMID: 34383472 PMC: 8903032. DOI: 10.1021/acs.analchem.1c02325.


References
1.
De Domenico I, Ward D, Nemeth E, Vaughn M, Musci G, Ganz T . The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci U S A. 2005; 102(25):8955-60. PMC: 1157058. DOI: 10.1073/pnas.0503804102. View

2.
Liu X, Yang F, Haile D . Functional consequences of ferroportin 1 mutations. Blood Cells Mol Dis. 2005; 35(1):33-46. DOI: 10.1016/j.bcmd.2005.04.005. View

3.
De Domenico I, Ward D, Bonaccorsi di Patti M, Jeong S, David S, Musci G . Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J. 2007; 26(12):2823-31. PMC: 1894773. DOI: 10.1038/sj.emboj.7601735. View

4.
Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt S, Moynihan J . Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000; 403(6771):776-81. DOI: 10.1038/35001596. View

5.
Drakesmith H, Schimanski L, Ormerod E, Merryweather-Clarke A, Viprakasit V, Edwards J . Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005; 106(3):1092-7. DOI: 10.1182/blood-2005-02-0561. View